(Q34389325)

1 August 2017

title

Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study (English)

1 reference

1 August 2017

0 references

6

Ralf Gold

1 reference

1 August 2017

author name string

Katrin Strassburger-Krogias

1

1 reference

1 August 2017

Gisa Ellrichmann

2

1 reference

1 August 2017

Christos Krogias

3

1 reference

1 August 2017

Peter Altmeyer

4

1 reference

1 August 2017

Andrew Chan

5

1 reference

1 August 2017

publication date

1 September 2014

1 reference

Therapeutic advances in neurological disorders

1 August 2017

published in

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

232-238

1 reference

Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Disease-modifying treatments for progressive multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Interferon beta for secondary progressive multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

The changing demographic pattern of multiple sclerosis epidemiology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Defining the clinical course of multiple sclerosis: Results of an international survey

6 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

6 July 2018

https://api.crossref.org/works/10.1177%2F1756285614544466

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206620

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285614544466

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285614544466

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285614544466

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285614544466

21 January 2018

Identifiers

DOI

10.1177/1756285614544466

1 reference

1 August 2017

1 reference

1 August 2017

1 reference